FGFR2 and bile duct carcinoma: Some of the most common genetic alterations observed in intrahepatic CCA are fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements, with an estimated incidence of 10%-15% among intrahepatic bile duct carcinomas.10FGFR2 rearrangements are predominantly found in patients with intrahepatic CCA and infrequently among patients with extrahepatic disease.2,11 Findings from clinical trials have demonstrated that inhibition of the FGFR pathway may be an effective therapeutic option for certain patients with CCA.